Xeris leverages proprietary XeriSol and XeriJect formulation technologies to create ready-to-use, non-aqueous injectable and infusible products for subcutaneous and intramuscular delivery. Its lead candidate is an investigational ready-to-use glucagon rescue pen for severe hypoglycemia, which is in late-stage development and being prepared for an NDA submission. The platforms aim to eliminate reconstitution, enable long-term room-temperature stability, reduce injection volume, and remove the need for IV infusion. Xeris plans to commercialize the glucagon rescue pen and use its technology to develop additional product candidates for both intermittent and chronic indications. The company intends to apply its ready-to-use glucagon to conditions such as post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, and as the glucagon component in a bi-hormonal closed-loop pump. Proceeds from recent financings are being directed toward NDA preparation, commercial readiness, and pipeline acceleration. Xeris Pharmaceuticals develops improved and differentiated injectable therapeutics using proprietary XeriSol and XeriJect formulation technologies that enable subcutaneous and intradermal delivery of highly concentrated, non‑aqueous, ready-to-inject formulations compatible with auto-injectors, multi-dose pens and pumps. Its lead product, G-Pen, is a novel glucagon injection intended to treat severe hypoglycemia; the company says the financing will support registration trials and the commercial launch of G-Pen. Xeris also plans clinical validation of additional products that leverage its formulation platform. The company highlights platform advantages including up to 1000-fold lower injection volumes, long-term room-temperature stability, and elimination of reconstitution and refrigeration. These attributes are presented as making products easier to use for patients, caregivers and health practitioners and as having the potential to reduce costs for payers and the healthcare system. Xeris is based in Austin, Texas. Xeris Pharmaceuticals develops novel formulations of injectable drugs using proprietary non-aqueous technologies. Its lead product is a room-temperature-stable glucagon solution built on the XeriSol™ platform. The company also offers XeriJect™ formulation technology enabling subcutaneous and intradermal delivery via auto-injectors, multi-dose pens and pumps. Xeris plans to use new funding to advance its lead glucagon product. Leadership includes President and CEO Douglas R. Baum, and the company is based in Austin, Texas. Xeris Pharmaceuticals is an Austin, Texas–based clinical-stage specialty biopharmaceutical company developing non-aqueous, room-temperature stable injectable formulations using its proprietary XeriSol™ technology. Its lead product is G-Pen™, a room-temperature stable glucagon injection intended for severe hypoglycemia; proceeds from the recent financing will accelerate G-Pen commercialization. The company also develops G-Pen Mini™, G-Pump™ (glucagon infusion), and CSI-glucagon (continuous subcutaneous infusion) for congenital hyperinsulinism, the latter having received FDA and EMA orphan designations. Xeris cited positive Phase 2a data for one program to be presented at an upcoming industry meeting. The company highlights formulation advantages such as up to 1000-fold lower injection volumes, elimination of reconstitution and refrigeration, and extended room-temperature shelf-life. Xeris said it will advance other programs using non-dilutive funds while using the new financing to support product development and commercialization. Xeris Pharmaceuticals, based in Austin, TX, develops patient-friendly injectable drugs using its non-aqueous XeriJect™ and XeriSol™ formulation-delivery platforms. The platforms allow Xeris to reformulate existing drugs as highly concentrated, ultra-low-volume, room-temperature stable formulations that do not require reconstitution. Its lead product is G-Pen™, a glucagon rescue pen containing a room-temperature stable, non-aqueous glucagon solution delivered as a 0.2 mL subcutaneous injection via an auto-injector. The company intends to use proceeds from a completed $1.5M Series A financing and a $1M Phase 2 Small Business Innovation Research grant from the NIDDK to conduct a Phase 1/2 trial of the G-Pen. John Kinzell serves as CEO, and Douglas Baum of CTAN will join the board as part of the financing.

Total raised

$145M

Funding rounds

7

Latest round

Series C

Latest activity

Mar 2018